Thursday, 4 March 2021

Proactive Investors Interview: BioLargo retires $650,000 in debt, following its plan to focus more on equity-based transactions

Source: Proactive Investors

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive it has paid off $650,000 in debt, the bulk of which was scheduled to mature in August 2021. Calvert says aside from the debt carried by its partially owned subsidiary Clyra Medical, only SBA loans and fixed-price convertible debt remain on BioLargo's balance sheet, which falls in line with the company's goals to aggressively reduce or eliminate its convertible debt instruments in favor of equity-based transactions.

Wednesday, 3 March 2021

BioLargo Invited to Present at Isle Utilities Industrial Water Treatment Virtual Event

Westminster, CA – March 3, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, today announced that it has been invited to present its AOS (Advanced Oxidation System) water treatment technology to decision-makers from diverse multinational companies at an Isle Utilities iTAG event.

At Isle Utilities’ iTAG (Industrial Technology Approval Group) events, which are held three times per year, water specialists, sustainability/innovation managers and other experts from global industries vote on promising water technologies they would like to learn about. Some iTAG member companies include Coca-Cola, Shell, and Proctor & Gamble.

In the March 2021 meeting, iTAG member companies voted to learn about BioLargo’s AOS technology. BioLargo Director of Strategic Marketing and Business Development Tonya Chandler will present the BioLargo AOS to iTAG member companies on March 4, 2021.

To learn more about the TAG program, watch Isle Utilities’ video:

BioLargo’s ground-breaking and patented Advanced Oxidation System (AOS) is a water treatment platform that provides high-level disinfection and consumes less electricity than competing technologies. Distinct from other disinfection-focused treatment systems, the AOS can also remove certain pharmaceutical micropollutants from water to provide added value across diverse water treatment applications.

The timing of BioLargo’s invitation to present at iTAG is auspicious, as the company is beginning to roll out the AOS through commercial trials, beginning with its first farm-wide water treatment and reuse project at a poultry farm in Alberta, Canada.

To learn more about the BioLargo AOS, visit www.biolargowater.com.

 

About Isle Utilities and iTAG

Isle is a medium sized, worldwide operating consultancy that has bridged exactly that gap successfully over the past decade for more than 150 global utilities. With 40 highly educated water professionals located all over the globe, Isle scouts, assesses and selects new water related technologies for the municipal water and wastewater utilities. In 2016, Isle has started to offer this service to industries with water and sustainability challenges too.  Each industrial company has sustainability objectives but it is typical that not all companies have the time to visit all the global trade shows, read every journal on the subject and invite all salesmen to site with that unique innovative solution to save water, energy and chemicals. At the same time, business developers of new innovative technologies have a hard time to draw the attention of these always extremely occupied industries. It was a catch 22 situation, until Isle set up iTAG.

Three times a year at iTAG-meetings (industrial Technology Approval Group) water specialists, sustainability/innovation managers and other experts from global industries gather. Some weeks prior to this meeting the members receive a list of the newest technological water related solutions which have been thoroughly vetted and compactly described by Isle’s experts. The members are invited to vote on the most promising technologies, which will be presented on the iTAG meeting. Over the last 10 years Isle has evaluated over 100 new technologies each year, varying from well protection technologies, treatment technologies, innovative sensors to cooling water technologies, wastewater solutions and novel ways to recover nutrients, sludge and energy.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act – caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday, 2 March 2021

BioLargo Strengthens Balance Sheet by Eliminating Debt as its Commercial Activities Expand

Westminster, CA – March 2, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it had paid off $650,000 in debt, the bulk of which was scheduled to mature in August of 2021.  Other than debt owed by its partially owned subsidiary Clyra Medical, only SBA loans and fixed-price convertible debt remain on BioLargo’s balance sheet. Of the SBA loans, management expects all but the $150,000 EIDL 30-year 3.75% APR loan to be forgiven. Of the fixed price convertible debt, $100,000 will convert to equity automatically at the April 20, 2021 maturity date, the $406,000 due in August 2021 may be converted by the investors at a fixed price of $0.14 at any time, and $50,000 is due in two years.

These actions are directly in line with the company’s goals to aggressively reduce or eliminate its convertible debt instruments in favor of equity-based transactions and eliminate costly interest expense. 

BioLargo President and CEO Dennis P. Calvert commented, “Our cash position is particularly strong, and we are confident in the progress of our business operations and expanding opportunities. Paying off this debt now helps reduce expense interest expense, as well as eliminate uncertainty of how the debt would be managed as it matures and comes due.”

Commercial milestones continue to grow at BioLargo with a few notable highlights:

·         An AOS water treatment unit was recently delivered to a municipal wastewater operation in Quebec Canada for pilot testing, and the company is on track for commencement of the AOS zero liquid discharge system project at poultry farm in Alberta, Canada, estimated to generate a half million dollars in revenue.

·         BioLargo’s engineering subsidiary continues to win major contracts with industrial clients, building a backlog of pending projects totaling more than $2 million over approximately the next 12 months. The group remains busy supporting BioLargo’s emerging commercial activities for the AEC and AOS water treatment systems.

·         BioLargo is exploring ways to expand its work with national water services company Garratt-Callahan beyond the development of a proprietary water treatment system.

·         Management is actively engaged with the EPA to expand its regulated claims for a series of products, including Clyraguard.

·         Expanded CupriDyne Clean misting system installations to municipal-owned solid-waste handling operations.

·         Readying for trials of the PFAS treatment solution (the BioLargo AEC) with multiple potential clients.

Dennis P. Calvert, BioLargo’s President & CEO commented, “We have solidified our reputation as a reliable innovator and solutions provider for sustainable high-value targets like clean water, clean air and a cleaner planet. We believe that our future revenue growth will accelerate dramatically through partnerships for large-scale manufacturing, distribution, and through marketing alliances. We have a strong foundation of technology, highly qualified team members and a driving purpose on which to build. As we have done for the last decade, innovations continue at BioLargo, and I’m personally very excited about some upcoming developments. We are proud of our record-breaking achievements but are certainly not satisfied as we believe we have only scratched the surface of our future revenue and profit potential.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Wednesday, 24 February 2021

BioLargo Answers Administration’s Urgent Call for Mitigation of PFAS Forever Chemicals

Highlights:

  • Federal enforcement of PFAS (per- and polyfluoroalkyl substances) in drinking water regulations is imminent
  • The water treatment sector is desperate for effective, economical solutions to remove PFAS from drinking water
  • BioLargo (OTCQB:BLGO) is rolling out its BioLargo AEC PFAS water treatment technology, which takes a novel and economical approach to removing these chemicals from water
  • The BioLargo solution produces far less PFAS-laden waste than traditional carbon-based technologies, leading to cost savings and a dramatically reduced carbon footprint
  • BioLargo’s PFAS solution will serve a multi-billion-dollar market while also aligning with the new administration’s focus on environmental issues such as water contamination

The Biden administration has wasted no time enacting new environmental policies since taking office last month. Our company, BioLargo (OTCQB:BLGO), is stepping up with exciting new technologies to take advantage of the opportunities created by President Biden’s far-reaching environmental agenda.

One of the new administration’s first moves was to announce final regulatory determinations on the safe levels of the widespread and toxic water contaminants called per- and polyfluoroalkyl substances (PFAS) in drinking water. This means the Federal Government has decided to create a national standard for what concentration of these chemicals will meet the threshold for regulatory action when found in drinking water supplies, and will now start the process of regulating the chemicals through the Safe Drinking Water Act.

The administration also gave advance notice that they may designate PFAS as federally regulated hazardous substances and/or regulated hazardous waste. These actions set off a long-anticipated race for municipalities around the country to identify and adopt water treatment systems that effectively and affordably remove the hard-to-treat chemicals from drinking water.

PFAS are a group of man-made chemicals found in countless household items like electronics, cleaning supplies, non-stick cookware and more. While many of these items are not known to be dangerous by virtue of containing PFAS, their ubiquitous manufacturing throughout the latter half of the 20th century led to widespread contamination of lakes, rivers, wells and groundwater throughout the U.S. In recent decades, there has been mounting evidence of the damage to human health caused by these chemicals, including cancer and hormone disorders.

Todd Haynes’s 2019 film Dark Waters told the story of how lawyer Robert Bilott (played by Mark Ruffalo) pursued DuPont in the late 1990s for contaminating Midwest communities with then-unregulated PFAS chemicals. While the issue of PFAS water contamination was well-documented by scientists at the time of the movie’s release, Dark Waters helped thrust the issue into the public eye.

In some areas such as Southern California, municipalities are already actively installing PFAS treatment systems, and as federal regulations go into effect, the adoption of PFAS treatment systems is expected to expand dramatically across the country. Drinking water utilities have struggled to find economical treatment technologies that can efficiently remove PFAS from water without stretching their budgets and generating mountains of toxic waste as a by-product of treatment. In Orange County, 11 water districts have launched a lawsuit against major PFAS polluters, including DuPont and 3M, to seek compensation for mandated well closures and water treatment system retrofitting needed to remove PFAS from their drinking water supplies.

At present, carbon filtration is the most common PFAS removal technology, but it comes with a serious downside – it generates huge volumes of PFAS-laden carbon waste that requires disposal. Usually, municipalities have to foot the bill for the costly transport and disposal of that PFAS-laden waste, which is normally done by incineration. Not only is PFAS carbon incineration costly, but a growing body of evidence suggests that it generates toxic volatile air contaminants (in addition to greenhouse gases) as a result of incomplete combustion of the PFAS chemicals. Disposal of PFAS-laden waste therefore remains a contentious issue (one that regulators are starting to look at) and municipalities would be wise to consider technologies that produce less PFAS-laden waste.  

Our company, BioLargo, an environmental technologies innovator (OTCQB:BLGO), has invented and is pilot-testing an innovative technology that removes PFAS chemicals from water faster and more cheaply than carbon filtration. Our technology, called the BioLargo AEC, uses electrolysis to extract PFAS molecules from water and deposit them onto proprietary membranes while using little electricity and no input chemistry. Proven to be more than 99.9% effective in removing PFAS from contaminated water, it produces only a fraction of the PFAS-laden waste that carbon filtration treatment creates, resulting in substantially lower waste disposal costs and better environmental outcomes.























How big is the market to solve this PFAS problem?

Experts have estimated that over the next decade, municipalities in the United States alone will spend billions of dollars a year on PFAS treatment systems. We at BioLargo aim to address this rapidly growing market by targeting municipalities interested in lower operating costs, decreased carbon footprints, increased constituent well-being and diminished regulatory risks associated with PFAS waste disposal. 

The BioLargo AEC is rolling out in pilots and commercial trials at municipalities in Southern California and the Midwest over the next year as more public officials and advocacy groups ratchet up the pressure to clean up the country’s PFAS contamination mess.

We at BioLargo are focused on creating a positive impact around the world with our innovative clean water, clean air and infection control solutions. Our company presents a scalable business model that targets high-impact CleanTech market opportunities like PFAS treatment while staying true to our mission statement to make life better.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BLGO holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BLGO has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act – caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday, 8 February 2021

BioLargo’s ONM Environmental Acquires EcoMist Trash Receptacle Spray Technology

Westminster, CA – February 8, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, today announced that its wholly owned subsidiary ONM Environmental has acquired a deodorizing and sanitizing technology, called EcoMist®, that helps raise the customer care bar for solid waste collectors to treat all types of waste receptacles in real time during pick up.  

EcoMist® is a device installed directly onto any waste collection vehicle that automatically sprays odor control products and/or sanitizer into refuse bins or dumpsters during the waste collection process. ONM plans to test market the product directly with its major solid waste handling customers by packaging it with its popular odor and VOC control product CupriDyne Clean. A video showing EcoMist® in operation can be viewed here: https://www.biolargo.com/ecomist-video

EcoMist® is easy to install and use. It works “out-of-the-box”, allowing customers to install the system themselves, and meaning ongoing sales will not require a significant investment in logistics and servicing. ONM’s acquisition of EcoMist® is part of its strategy to grow revenues of its air quality control division through chemistry deployment systems that lead to more scalable sales of its disruptive odor and VOC control product CupriDyne® Clean. It also helps ensure ONM can provide the largest waste handling companies in the country with a broad range of tools to solve their odor and VOC control challenges in all facets of their business.

ONM’s only obligation under the acquisition agreement is a 10% royalty on EcoMist® system sales.

President of ONM Environmental Joseph Provenzano commented, “To the best of our knowledge the EcoMist system is one of a kind.  We believe it is a good fit to enhance business growth and another example of how we continue to deliver valuable solutions for our customers while helping keep our environment cleaner, safer and healthier, as we pursue our overarching mission to ‘make life better’”.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act – caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Thursday, 4 February 2021

BioLargo teams up with Garratt-Callahan to co-create and develop a wastewater treatment product

BioLargo, Inc. (OTCQB:BLGO) CEO Dennis Calvert tells Proactive said it has teamed up with Garratt-Callahan Company, a national industrial water treatment company, to co-create and develop a wastewater treatment product that will salvage usable water from commercial facilities wastewater streams.

Calvert says the shared goal is to design and manufacture a new piece of wastewater treatment equipment centered around a new patented water treatment process developed by Garratt-Callahan to reduce wastewater discharged from commercial facilities.

Tuesday, 2 February 2021

BioLargo and Garratt-Callahan Team Up for Product Development Project

Westminster, CA – February 2, 2021 – BioLargo, Inc. (OTCQB:BLGO), developer of cutting-edge environmental technologies and a full-service engineering firm, announced that it has teamed up with Garratt-Callahan Company, a national industrial water treatment company, to co-create and develop a wastewater treatment product that will salvage usable water from commercial facilities wastewater streams.

Their mutual concern for the environment and the care and conservation of water make the collaboration between BioLargo and Garratt-Callahan a symbiotic match.  BioLargo’s mission to provide unique disruptive solutions to deliver clean air, clean water and a clean, safe environment combined with Garratt-Callahan’s 116 years of experience and commitment to provide safer water treatment and deliver unrivalled customer service make for a formidable combination.

The shared goal is to design and manufacture a new piece of wastewater treatment equipment centered around a new patented water treatment process developed by Garratt-Callahan to reduce wastewater discharged from commercial facilities. BioLargo’s engineering division (BioLargo Engineering, Science & Technologies) will design, build and pilot a prototype of the new system. When refined, the two organizations have agreed to offer the system commercially to Garratt-Callahan customers and select BioLargo distributors, with BioLargo serving as the equipment’s ongoing manufacturer. The collaborative team targets having full-scale units in operation in mid to late 2021 or early 2022. Both companies expect strong demand for this product offering among its wastewater treatment customers.

Garratt-Callahan has signed a purchase order with BioLargo to permit work to begin. The two organizations believe this will be the first collaboration of many. Discussions are underway between leaders at both companies regarding the future utilization of BioLargo’s other technology assets to serve their customers’ needs.

President and CEO of BioLargo Dennis P. Calvert commented, “This is a tremendous opportunity for BioLargo and Garratt-Callahan to work together to address customers’ pressing wastewater treatment needs. Garratt-Callahan has a great reputation and history as a reliable and innovative water treatment services company, and they recognized BioLargo as a reliable innovator in the water treatment technology space. This collaboration is a perfect fit with shared corporate values of fairness, honesty and integrity. We believe we will help solve important water treatment challenges that Garratt-Callahan’s customers face. We look forward to sharing more information as the project progresses.”


About Garratt-Callahan

Their products and services are utilized throughout the United States by clients in various commercial and industrial applications, including cooling towers, closed systems, boilers, steam condensate systems, wastewater systems, membrane separation systems and bioaugumentation.

Garratt-Callahan is an Industrial Water Treatment Company. Founded in 1904, G-C has been providing water treatment products and service for over 100 years. We manufacture a complete line of water treatment products to control scale, corrosion and sludge buildup on heat transfer surfaces in steam and hot water boilers and cooling systems.

G-C is dedicated to providing the highest quality products, engineering excellence, and long-term quality service to our customers at a fair price. G-C is a privately owned company that is active in every major market with a wide range of products to treat boiler and cooling water, closed systems, wastewater, and potable water. G-C’s laboratory maintains state-of-the-art analytical instrumentation and a staff of skilled and experienced professionals to help diagnose and solve the most difficult water treatment problems. Our quality management system is ISO9001 certified.

G-C is proud of our safety record. We provide instruction, equipment and products to help our customers ensure a safe workplace. Whether your business is a hotel, hospital, food plant, manufacturing plant, or any industrial facility; we can supply the necessary certification for any Federal or State regulations, professional requirements or local codes.

With offices/plants in Burlingame, CA, Farmers Branch, TX, Addison, IL, Atlanta, GA and Edison NJ; G-C will help you prevent water problems with your equipment and facilities.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BLGO holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BLGO has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.